Drug Profile


Alternative Names: BI836845

Latest Information Update: 29 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Eli Lilly
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Somatomedin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer; Prostate cancer
  • Phase I Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 04 May 2017 Phase-I clinical trials in Breast cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA, Japan (IV) (NCT03099174)
  • 04 May 2017 Boehringer Ingelheim initiates a phase I trial in Breast cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in France and Spain (NCT03099174)
  • 02 Apr 2017 Pharmacodynamics data from preclinical studies in Prostate cancer presented at the Annual Meeting of the American Association of Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top